D. Steven Rubin's most recent trade in Entera Bio Ltd was a trade of 43,405 Stock Option (right to buy) done . Disclosure was reported to the exchange on Aug. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Entera Bio Ltd | Mr. Steven D. Rubin | Director | 07 Aug 2026 | 43,405 | 43,405 | - | - | Stock Option (right to buy) | ||
| Entera Bio Ltd | Mr. Steven D. Rubin | Director | 07 Aug 2026 | 33,368 | 33,368 | - | - | Stock Option (right to buy) | ||
| Entera Bio Ltd | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2026 | 19,117 | 34,117 (0%) | 0% | 0 | Ordinary Shares, par value NIS 0.0000769 per share | |
| Opko Health Inc | Mr. Steven D. Rubin | Director, Executive VP-Administration | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.22 per share. | 24 Jul 2026 | 53,266 | 6,571,966 (0%) | 0% | 1.2 | 64,985 | Common Stock |
| Niagen Bioscience Inc | Mr. Steven D. Rubin | Director | 24 Jun 2026 | 31,746 | 31,746 | - | - | Stock Option (right to buy) | ||
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 08 Jun 2026 | 4,018 | 4,018 | - | - | Stock Option (Right to Buy) | ||
| Red Violet Inc | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 2,179 | 147,767 (1%) | 0% | - | Common Stock | |
| Entera Bio Ltd | Mr. Steven D. Rubin | Director | Purchase of securities on an exchange or from another person at price $ 1.49 per share. | 12 Feb 2026 | 5,000 | 15,000 (0%) | 0% | 1.5 | 7,450 | Ordinary Shares, par value NIS 0.0000769 per share |
| Entera Bio Ltd | Mr. Steven D. Rubin | Director | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 09 Feb 2026 | 10,000 | 10,000 (0%) | 0% | 1.2 | 12,000 | Ordinary Shares, par value NIS 0.0000769 per share |
| Cocrystal Pharma Inc | Mr. Steven D. Rubin | Director | 09 Jan 2026 | 16,410 | 16,410 | - | - | Stock Options (Right to Buy) | ||
| Red Violet Inc | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2025 | 4,450 | 145,588 (1%) | 0% | - | Common Stock | |
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 19 Sep 2025 | 179,854 | 179,854 | - | - | Stock Option (Right to Buy) | ||
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 19 Sep 2025 | 1,875 | 1,875 | - | - | Restricted Stock Units | ||
| Eloxx Pharma | Mr. Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2025 | 1,875 | 14,625 (0%) | 0% | - | Common Stock | |
| Niagen Bioscience Inc | Mr. Steven D. Rubin | Director | 24 Jun 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | ||
| Opko Health Inc | Mr. Steven D. Rubin | Director, Executive VP-Administration | 27 May 2025 | 437,500 | 437,500 | - | - | Stock Option (Right to Buy) | ||
| Red Violet Inc | Mr. Steven D. Rubin | Director | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 19 Mar 2025 | 10,000 | 141,138 (1%) | 0% | 38.9 | 389,300 | Common Stock |
| Eloxx Pharma | Mr. Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 15,750 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 24 Jan 2025 | 3,750 | 3,750 | - | - | Restricted Stock Units | ||
| Red Violet Inc | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 8,000 | 151,138 (1%) | 0% | - | Common Stock | |
| Eloxx Pharma | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 12,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Cocrystal Pharma Inc | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2024 | 18,957 | 2,660,242 (5%) | 0% | - | Common Stock | |
| Opko Health Inc | Mr. Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2024 | 437,500 | 6,625,232 (0%) | 0% | 0 | Common Stock | |
| Niagen Bioscience Inc | Mr. Steven D. Rubin | Director | 20 Jun 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | ||
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 24 Jan 2024 | 7,500 | 7,500 | - | - | Restricted Stock Units | ||
| Opko Health Inc | Mr. Steven D. Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 0.87 per share. | 05 Jan 2024 | 10,000 | 6,187,732 (0%) | 0% | 0.9 | 8,669 | Common Stock |
| Red Violet Inc | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2023 | 10,800 | 143,138 (1%) | 0% | - | Common Stock | |
| Opko Health Inc | Mr. Steven D. Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 1.30 per share. | 10 Nov 2023 | 10,000 | 6,177,732 (0%) | 0% | 1.3 | 13,000 | - |
| Cocrystal Pharma Inc | Mr. Steven D. Rubin | Director | 18 Jul 2023 | 17,233 | 17,233 | - | - | Stock Options (Right to Buy) | ||
| Niagen Bioscience Inc | Mr. Steven D. Rubin | Director | 15 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | ||
| Niagen Bioscience Inc | Mr. Steven D. Rubin | Director | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 25 May 2023 | 7,000 | 7,000 (0%) | 0% | 1.5 | 10,220 | Common Stock |
| Opko Health Inc | Mr. Steven D. Rubin | Director, Executive VP-Administration | 18 May 2023 | 700,000 | 700,000 | - | - | Stock Option (Right to Buy) | ||
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 30 Jan 2023 | 2,859 | 2,859 | - | - | Stock Options (Right to Buy) | ||
| Red Violet Inc | Mr. Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2022 | 10,800 | 132,338 (1%) | 0% | - | Common Stock | |
| Cocrystal Pharma Inc | Mr. Steven D. Rubin | Director | 25 Jul 2022 | 188,000 | 188,000 | - | - | Stock Options (Right to Buy) | ||
| Niagen Bioscience Inc | Mr. Steven D. Rubin | Director | 16 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | ||
| Eloxx Pharma | Mr. Steven D. Rubin | Director | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Options (Right to Buy) |